<DOC>
	<DOCNO>NCT02992977</DOCNO>
	<brief_summary>This open-label Phase 1 study determine safety , feasibility , tolerability single-agent treatment AutoSynVax™ vaccine subject advance cancer life expectancy ≥6 month . A minimum 6 ( ≤20 ) subject enrolled receive biweekly subcutaneous injection 240 μg AutoSynVax™ vaccine + 50 μg QS-21 Stimulon® adjuvant 1 year .</brief_summary>
	<brief_title>Safety Tolerability Study AutoSynVax™ Vaccine Subjects With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Diagnosis advance cancer refractory standard therapy . 2 . No curative therapy exist subject receive appropriate therapy know associated clinical benefit condition , exist . 3 . Minimum estimated life expectancy 6 month absence treatment . 4 . Age 18 year old . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 . 6 . Adequate bone marrow function ( absolute neutrophil count [ ANC ] ≥1,500/mm3 ; absolute lymphocyte count [ ALC ] ≥500/mm3 ; platelet count 100,000/mm3 ) , adequate liver function ( serum glutamic oxaloacetic transaminase [ SGOT ] /aspartate aminotransferase [ AST ] alkaline phosphatase ≤2.5 time institutional upper limit normal [ IULN ] , total bilirubin &lt; 1.5 mg/dL ) , adequate renal function ( creatinine &lt; 1.5 x IULN ) . 7 . Adequate cardiac function ( New York Heart Association [ NYHA ] class ≤II ) . 8 . Available tissue archival tissue sample tissue biopsy do initial screen , . 9 . All participant must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . 10 . Ability understand willingness sign write informed consent document . 1 . Receipt anticancer medication investigational drug within follow interval first administration study drug : 1 . ≤14 day chemotherapy , target small molecule therapy , radiation therapy . Subjects must also radiation pneumonitis result treatment , participate study chronic corticosteroid radiation pneumonitis . A 1week washout permit palliative radiation nonCNS disease sponsor approval . Note : Bisphosphonates denosumab permitted medication . Novel image agent Phase 1 safety data demonstrate therapeutic activity also permit . 2 . ≤28 day prior immunotherapy . 3 . ≤28 day prior monoclonal antibody use anticancer therapy exception denosumab . 4 . ≤7 day immunosuppressivebased treatment reason . Systemic corticosteroid allow . Note : Use inhale topical corticosteroid use radiographic procedure permit . Note : The use physiologic corticosteroid replacement therapy may approve consultation sponsor . 5 . ≤28 day first dose investigational study drug device . 2 . Receipt investigational agent anticancer therapy treatment AutoSynVax™ vaccine . 3 . Diagnosis immunodeficiency actively receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 4 . Corticosteroid dependency . 5 . Requirement immunosuppressive medication aside corticosteroid . 6 . Active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy exception rule . Subjects require intermittent use bronchodilator local steroid injection exclude study . Subjects hypothyroidism stable hormone replacement Sjogren 's syndrome exclude study . 7 . Brain metastasis leptomeningeal spread disease . 8 . Known endocrinopathies . 9 . History current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 10 . Known medical , psychiatric substance abuse disorder would preclude participation study . 11 . Uncontrolled intercurrent illness , include , limited , ongoing active infection , interstitial lung disease active , noninfectious pneumonitis , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 12 . Known positive human immunodeficiency virus ( HIV ) . Testing required absence history high index suspicion . 13 . Receipt live vaccine within 30 day prior first dose trial treatment . 14 . Intolerance prior immunotherapy treatment necessitate cessation therapy . 15 . History intolerance allergic reaction attribute compound similar chemical biologic composition AutoSynVax™ vaccine QS21 Stimulon® adjuvant . 16 . Inability comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Vaccine , neoantigen</keyword>
</DOC>